Shareholders made their thoughts clear on medical technology company Belluscura PLC (AIM:BELL)’s interim results today, with shares diving 14% as of 10.45am.
Revenues and earnings figures objectively justified this response, with top-line sales falling a third year on year to US$400,000 (£321,000) and adjusted EBITDA falling 30% to US$2.9 million.
Total after-tax losses for the period after currency conversions came to US$4.4 million.
Belluscura raised a combined total of US$8.8 million (£7 million) through debt and equity issuances in the period. Bet cash increased from US$2 million at the end of 2022 to US$3.8 million as of 30 June.
Belluscura distributes X-PLOR portable oxygen device.